Comparison of current and new pneumococcal conjugate vaccines used for infant immunisation
Pneumococcal bacteria can cause serious and potentially life-threatening illnesses in babies, including chest infections (pneumonia), blood poisoning (sepsis), and meningitis. The NHS currently offers infants a vaccine called PCV13, which protects against 13 common strains of these bacteria. However, other strains can still cause severe disease. This study, led by the University of Oxford, looks at newer vaccines called PCV15 and PCV20. These updated jabs are designed to protect against 15 or 20 bacterial strains. Researchers want to find out how well they trigger an immune response and protect babies when given as part of their routine childhood schedule. Healthy babies aged 8 to 10 weeks who were born full-term and have not yet had their first routine immunisations may take part. Families receive all scheduled infant vaccinations, sometimes at home, alongside 24-hour support from a study doctor.
At a glance
What is this study about?
Pneumococcal disease is an infection caused by bacteria called Streptococcus pneumoniae. It can lead to very serious illnesses such as pneumonia, meningitis (swelling around the brain), and sepsis (blood poisoning). Babies under two years old are at the highest risk of becoming seriously unwell from these infections.
At present, babies in the UK receive a routine vaccine known as PCV13, which protects against 13 common types of pneumococcal bacteria. While this vaccine has saved many lives, there are more than 90 different types of pneumococcal bacteria in total. In recent years, doctors have seen an increase in infections caused by types that PCV13 does not cover.
This study is testing two newer vaccines, named PCV15 and PCV20, which cover 15 and 20 bacterial types respectively. Researchers want to see if these newer vaccines provide broader, safe protection for babies. The results will help healthcare experts decide the best vaccination schedule to protect children across the UK in the future.
Key takeaways
- Tests newer vaccines (PCV15 and PCV20) designed to protect against more strains of pneumococcal bacteria.
- Open to healthy, full-term babies aged 8 to 10 weeks who have not yet had their first routine immunisations.
- Includes all routine NHS baby vaccines up to 12 months of age, with possible home visits.
- Involves two small blood tests with numbing cream and gentle nose swabs to check immune responses.
- Parents receive 24-hour access to a specialist study doctor for advice throughout the trial.
Who may be eligible?
This study is open to healthy babies who are between 8 and 10 weeks old (up to 10 weeks and a half) and are due for their first infant immunisations. To take part, babies must have been born at full term (at or after 37 weeks of pregnancy), and their parent or legal guardian must be at least 16 years old.
Babies cannot take part if they have already had their first routine childhood vaccines (although having had the Hepatitis B or BCG jab at birth is allowed). Babies who have serious long-term illnesses, heart or neurological conditions, bleeding disorders, or problems with their immune system are also not eligible.
In addition, infants with known severe allergies to vaccine ingredients, antibiotics like neomycin, or latex cannot join. A study doctor will review your baby's health details with you to ensure taking part is completely safe.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- My baby is currently between 8 and 10 weeks old.
- My baby was born at 37 weeks of pregnancy or later.
- My baby has not yet received their first set of routine childhood jabs.
- My baby has no major long-term health, nerve, or immune system conditions.
- I am a parent or legal guardian aged 16 or over.
What does participation involve?
Taking part lasts from when your baby is around 8 to 10 weeks old until they are 13 months old. Your baby will be placed into one of four study groups at random (by chance). Depending on the group, they will receive their pneumococcal vaccine at 3 or 4 months and 12 months, or at 2, 4, and 12 months. All other routine NHS baby vaccines are given alongside these jabs.
Some study visits may take place in your own home or at a local research clinic. During the study, your baby will have two small blood samples taken (at around 4 to 5 months and 13 months) to check how their immune system has responded. A numbing cream is always offered to keep your baby comfortable. The study team will also take three or four gentle nose swabs using a soft cotton bud. Throughout the trial, you will have direct telephone access to a paediatric study doctor 24 hours a day.
Potential risks and benefits
Locations (4)
- Bristol Vaccine CentreCity onlyBristol, England
- The University of Nottingham Health Service Cripps Health CentreCity onlyNottingham, England
- St George's University Hospitals NHS Foundation Trust and St. George’s Vaccine Institute (SGVI) Centre for Neonatal and Paediatric Infection DiseasesCity onlyLondon, England
- Southampton General HospitalApproximateSouthampton, England
Common questions
Will my baby still receive their normal childhood vaccines?
Yes. Your baby will receive all standard childhood immunisations recommended up to 12 months of age as part of the study visits.
Are the newer vaccines safe?
Yes. These vaccines have already been tested and are licensed for use in the UK, Europe, or the United States.
Does the blood test hurt my baby?
The study team uses a skin-numbing cream before taking the sample to reduce any pain, and only very small amounts of blood are taken.
Can visits happen at home?
In many areas, study nurses can visit you at home to give vaccinations and carry out health checks, saving you travel.
Can I leave the study if I change my mind?
Yes. You are free to withdraw your baby from the study at any point without giving a reason, and your regular NHS care will continue as normal.
How to find out more
Denis Murphy
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.